title: The effectiveness of audiometric evaluation in drug treatment for otospongiosis.
abstract: Otospongiosis is a primary osteodystrophy of the otic capsule that affects genetically predisposed individuals and leads to a progressive hearing loss.
  
  
  OBJECTIVE
  To evaluate the applicability of audiometric evaluation during drug treatment for otospongiosis.
  
  
  METHODS
  A prospective, randomized, controlled, double-blind study involving 26 patients with clinical, audiometric and CT scan image of otosclerosis. Patients eligible for the study were divided into three groups (A, B and C) and received treatment with alendronate sodium (B), sodium fluoride (C) and placebo (A) for 6 months. After this period they were submitted to new tests.
  
  
  RESULTS
  There were not statistically significant differences between air and bone conduction (gap). We also found no differences in the speech recognition threshold (SRT) and speech discrimination (IRF) between before and after treatment.
  
  
  CONCLUSIONS
  After six months of drug treatment the audiometric evaluation kept the same hearing thresholds, suggesting stabilization of the otospongiotic lesions.
authors.affiliation: ENT Residency Program at Instituto Cema, Paulista Medical School, Federal University of São Paulo.
authors.forename: Andy de Oliveira
authors.initials: Ade O
authors.lastname: Vicente
authors.forename: Hélio K
authors.initials: HK
authors.lastname: Yamashita
authors.forename: Oswaldo Laércio Mendonça
authors.initials: OL
authors.lastname: Cruz
authors.forename: Flavia Barros
authors.initials: FB
authors.lastname: Suzuki
authors.forename: Norma de Oliveira
authors.initials: Nde O
authors.lastname: Penido
mesh_terms: D000328:Adult; D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D001299:Audiometry; D001309:Auditory Threshold; D001844:Bone Conduction; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D016022:Case-Control Studies; D004311:Double-Blind Method; D005260:Female; D034381:Hearing Loss / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010040:Otosclerosis / Q000188:drug therapy*; D011446:Prospective Studies; D012969:Sodium Fluoride / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D050071:Bone Density Conservation Agents; D012969:Sodium Fluoride; D019386:Alendronate